1
|
Yadav P, Bhatia R, Vasisht S, Sethi J. Patch test with multiple antipyretics in a case of fixed drug eruption in a child. Contact Dermatitis 2024; 90:422-423. [PMID: 38146069 DOI: 10.1111/cod.14487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Revised: 10/31/2023] [Accepted: 12/09/2023] [Indexed: 12/27/2023]
Affiliation(s)
- Piyush Yadav
- Department of Dermatology, Venereology, and Leprosy, All India Institute of Medical Sciences, Rishikesh, India
| | - Riti Bhatia
- Department of Dermatology, Venereology, and Leprosy, All India Institute of Medical Sciences, Rishikesh, India
| | - Shivani Vasisht
- Department of Dermatology, Venereology, and Leprosy, All India Institute of Medical Sciences, Rishikesh, India
| | - Jyoti Sethi
- Department of Dermatology, Venereology, and Leprosy, All India Institute of Medical Sciences, Rishikesh, India
| |
Collapse
|
2
|
Al-Ansari RY, Almuhaish LA, Hassan KA, Fadoul T, Woodman A. A Saudi Woman with Ceftriaxone Induced Fixed Drug Eruption. Case Rep Dermatol Med 2024; 2024:9975455. [PMID: 38523830 PMCID: PMC10959582 DOI: 10.1155/2024/9975455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Revised: 02/24/2024] [Accepted: 03/04/2024] [Indexed: 03/26/2024] Open
Abstract
Background A fixed drug eruption (FDE) is an immunological cutaneous adverse reaction, classified as a cutaneous adverse drug reaction (CADR) and characterized by well-defined lichenoid lesions that occur at the same site each time. Ceftriaxone is a third-generation antibiotic of cephalosporin antibiotics of the beta-lactam antibiotic family, which has typical in vitro activity against many Gram-negative aerobic bacteria. This is the first clinical case from Saudi Arabia and the fifth in the world to document a woman's experience with recurrent FDE after repeated ceftriaxone use. Case Report. A 25-year-old Saudi woman with a known case of sickle cell anemia (SCA) with a history of avascular necrosis of the right hip after replacement was hospitalized with a pain crisis triggered by an upper respiratory tract infection. The patient denied having a history of allergy previously. Due to fever, leukocytosis, and active follicular tonsillitis, ceftriaxone was started. However, a few hours later she developed lip edema and a fixed drug eruption measuring 7 × 11 cm on the left side of her back. The lesion reformed over a hyperpigmented lesion (4 × 8 cm) that the patient did not report upon initial examination. It turned out that this was due to the intravenous administration of ceftriaxone, a year ago in another hospital. An allergy to ceftriaxone was considered, and steroids and antihistamines were started. The case was labeled as ceftriaxone induced FDE. Conclusion Ceftriaxone induced FDE is an uncommon type of allergic reaction that has been reported infrequently. Understanding this condition and the mechanism by which FDE becomes recurrent with the same previous fixed lesion is of great importance for both academic and future research purposes.
Collapse
Affiliation(s)
- Rehab Y. Al-Ansari
- Adult Hematology Unit, Internal Medicine Department, King Fahd Military Medical Complex, Dhahran, Saudi Arabia
| | | | - Khaled Abdullah Hassan
- General Medicine Unit, Internal Medicine Department, King Fahd Military Medical Complex, Dhahran, Saudi Arabia
| | - Tawasoul Fadoul
- General Medicine Unit, Internal Medicine Department, King Fahd Military Medical Complex, Dhahran, Saudi Arabia
| | | |
Collapse
|
3
|
Jayasundera J, Watts TJ. Skin Testing in Fixed Drug Eruptions: A Useful and Safe Tool? THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE 2024; 12:469-471. [PMID: 38336399 DOI: 10.1016/j.jaip.2023.11.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Accepted: 11/10/2023] [Indexed: 02/12/2024]
Affiliation(s)
- Joseph Jayasundera
- Department of Respiratory Medicine & Allergy, Homerton Healthcare NHS Foundation Trust, London, United Kingdom
| | - Timothy J Watts
- Department of Respiratory Medicine & Allergy, Homerton Healthcare NHS Foundation Trust, London, United Kingdom; National Heart & Lung Institute, Imperial College London, London, United Kingdom.
| |
Collapse
|
4
|
Traineau H, Milpied B, Soria A, Assier H, Tetart F, Bernier C, Le Bouëdec MCF, Gener G, Kurihara F, Bauvin O, Delauney J, Amsler E, Bara C, Pelletier F, Valois A, Castelain F, de Risi Pugliese T, Hamelin A, Barbaud A. In Situ Patch Test and Repeated Open Application Test for Fixed Drug Eruption: A Multicenter Study. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE 2024; 12:460-468. [PMID: 37863314 DOI: 10.1016/j.jaip.2023.10.021] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 09/26/2023] [Accepted: 10/10/2023] [Indexed: 10/22/2023]
Abstract
BACKGROUND Few studies have evaluated allergy workup in fixed drug eruption (FDE) in a large population. OBJECTIVE To evaluate the sensitivity of a standardized allergy workup for diagnosing the cause of FDE, with a focus on in situ repeated open application tests (ROATs). METHODS In a retrospective multicenter study, we analyzed the practice of conducting a complete allergy workup for the etiological diagnosis of FDE. It consisted of 3 steps: in situ patch tests (PTs) for all cases except pure mucosal involvement, followed by in situ ROAT if in situ PT results were negative, and finally a drug challenge (DC). The in situ ROAT involved daily application of the suspected drug on a previously affected FDE site for 7 days. RESULTS Of 98 suspected FDE cases, 61 patients (median age 61 y; male-to-female ratio 1.8) with a complete allergy workup were included. In 4 cases, even the DC yielded negative results. Among the remaining 57 patients with a positive workup, implicated drugs included paracetamol (12 cases), β-lactams (11 cases), imidazoles (9 cases, including 5 with metronidazole), nonsteroidal anti-inflammatory drugs (8 cases), iodinated contrast media (4 cases), cotrimoxazole (3 cases), and various other drugs in 10 patients. The diagnosis was confirmed by in situ PT in 17 of 54 cases (31.5%), in situ ROAT in 14 of 40 cases (35%) (with 4 cases showing remote reactivation of FDE sites), and DC in 26 cases. CONCLUSIONS The sequential allergy workup involving successively in situ PT, in situ ROAT, and DC is a reliable and safe method for diagnosing the cause of FDE. In situ tests exhibited a sensitivity of over 50%.
Collapse
Affiliation(s)
- Hélène Traineau
- Médecine Sorbonne Universiy, Dermatology and allergology department, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Brigitte Milpied
- Centre hospitalo-universitaire (CHU) de Bordeaux, Dermatology department, Saint André hospital, Bordeaux, France
| | - Angèle Soria
- Cimi-Paris Inserm 1135, AP-HP, Sorbonne University, Hôpital Tenon, Dermatology and allergology department, Paris, France
| | - Haudrey Assier
- Dermatology department, AP-HP, Henri Mondor hospital, Créteil, France
| | | | | | | | - Gwendeline Gener
- Dermatology department, AP-HP, Henri Mondor hospital, Créteil, France
| | - Flore Kurihara
- Médecine Sorbonne Universiy, Dermatology and allergology department, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | | | - Juliette Delauney
- CHU d'Angers, Dermatology department, Centre hospitalier de Cholet, Angers, France
| | - Emmanuelle Amsler
- Médecine Sorbonne Universiy, Dermatology and allergology department, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Corina Bara
- Dermatology department, Centre hospitalier du Mans, Le Mans, France
| | | | - Aude Valois
- Dermatology department, Hôpital d'instruction des armées Sainte Anne, Toulon, France
| | | | - Tullia de Risi Pugliese
- Médecine Sorbonne Universiy, Dermatology and allergology department, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Aurore Hamelin
- Médecine Sorbonne Universiy, Dermatology and allergology department, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Annick Barbaud
- Médecine Sorbonne Universiy, Dermatology and allergology department, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.
| |
Collapse
|
5
|
Paulmann M, Reinkemeier F, Lehnhardt M, Mockenhaupt M. Case report: Generalized bullous fixed drug eruption mimicking epidermal necrolysis. Front Med (Lausanne) 2023; 10:1125754. [PMID: 37644986 PMCID: PMC10461315 DOI: 10.3389/fmed.2023.1125754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Accepted: 07/13/2023] [Indexed: 08/31/2023] Open
Abstract
Generalized bullous fixed drug eruption (GBFDE) is the most severe form of fixed drug eruption and can be misdiagnosed as epidermal necrolysis (EN). We report the case of a 42-year-old male patient presenting with more than 50% skin detachment without defined areas of exanthema or erythema and a history of one prior event of EN caused by acetaminophen (paracetamol), allopurinol, or amoxicillin 1.5 years ago. The initial diagnosis was GBFDE or EN. The histology of a skin biopsy was unable to distinguish between the two diseases. The course of the disease, the later clinical presentation, and the medical and medication history, however, were in favor of a diagnosis of GBFDE with two potentially culprit drugs: metamizole and ibuprofen. Moxifloxacin, enoxaparin sodium, hydromorphone, and insulin human were administered concomitantly, which makes them suspicious as well. Unfortunately, the patient received an additional dose of metamizole, one of the possible causative drugs, and he developed another bullous reaction within 1 month. This led to the diagnosis of GBFDE due to metamizole. This report highlights the challenges of distinguishing two rare diseases and elucidates the importance of distinct clinical presentation and detailed medication history.
Collapse
Affiliation(s)
- Maren Paulmann
- Dokumentationszentrum schwerer Hautreaktionen (dZh), Department of Dermatology, Medical Center—University of Freiburg, Freiburg, Germany
| | - Felix Reinkemeier
- Department of Plastic Surgery and Hand Surgery, Burn Center, Sarcoma Center, Berufsgenossenschaft University Hospital Bergmannsheil Bochum, Bochum, Germany
| | - Marcus Lehnhardt
- Department of Plastic Surgery and Hand Surgery, Burn Center, Sarcoma Center, Berufsgenossenschaft University Hospital Bergmannsheil Bochum, Bochum, Germany
| | - Maja Mockenhaupt
- Dokumentationszentrum schwerer Hautreaktionen (dZh), Department of Dermatology, Medical Center—University of Freiburg, Freiburg, Germany
| |
Collapse
|
6
|
Rodríguez-Pérez R, de las Vecillas L, Cabañas R, Bellón T. Tools for Etiologic Diagnosis of Drug-Induced Allergic Conditions. Int J Mol Sci 2023; 24:12577. [PMID: 37628756 PMCID: PMC10454098 DOI: 10.3390/ijms241612577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 08/03/2023] [Accepted: 08/06/2023] [Indexed: 08/27/2023] Open
Abstract
Drug hypersensitivity reactions are a serious concern in clinical practice because they can be severe and result in lifelong sequelae. An accurate diagnosis and identification of the culprit drug is essential to prevent future reactions as well as for the identification of safe treatment alternatives. Nonetheless, the diagnosis can be challenging. In vivo and in vitro tests can be helpful, although none are conclusive; therefore, the tests are not usually performed in isolation but as part of a diagnostic algorithm. In addition, some in vitro tests are only available in research laboratories, and standardization has not been fully accomplished. Collaborating research is needed to improve drug hypersensitivity reaction diagnosis. In this review, we update the current available in vivo and in vitro tools with their pros and cons and propose an algorithm to integrate them into clinical practice.
Collapse
Affiliation(s)
- Rosa Rodríguez-Pérez
- Institute for Health Research Hospital Universitario La Paz (IdiPAZ), Paseo Castellana 261, 28046 Madrid, Spain; (L.d.l.V.); (R.C.); (T.B.)
| | - Leticia de las Vecillas
- Institute for Health Research Hospital Universitario La Paz (IdiPAZ), Paseo Castellana 261, 28046 Madrid, Spain; (L.d.l.V.); (R.C.); (T.B.)
- Allergy Department, La Paz University Hospital, Paseo Castellana 261, 28046 Madrid, Spain
- PIELenRed Consortium, 28046 Madrid, Spain
| | - Rosario Cabañas
- Institute for Health Research Hospital Universitario La Paz (IdiPAZ), Paseo Castellana 261, 28046 Madrid, Spain; (L.d.l.V.); (R.C.); (T.B.)
- Allergy Department, La Paz University Hospital, Paseo Castellana 261, 28046 Madrid, Spain
- PIELenRed Consortium, 28046 Madrid, Spain
- Center for Biomedical Research Network on Rare Diseases (CIBERER U754), 28046 Madrid, Spain
| | - Teresa Bellón
- Institute for Health Research Hospital Universitario La Paz (IdiPAZ), Paseo Castellana 261, 28046 Madrid, Spain; (L.d.l.V.); (R.C.); (T.B.)
- PIELenRed Consortium, 28046 Madrid, Spain
| |
Collapse
|
7
|
Pereira AS, Flor D, Gonçalo M. A case of fixed drug eruption from cetirizine with cross-reaction to levocetirizine and hydroxyzine. Contact Dermatitis 2023; 88:318-319. [PMID: 36562721 DOI: 10.1111/cod.14270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Revised: 12/08/2022] [Accepted: 12/20/2022] [Indexed: 12/24/2022]
Affiliation(s)
- Ana Sofia Pereira
- Department of Dermatology, Coimbra University Hospital, Coimbra, Portugal
| | - Duarte Flor
- Department of Dermatology, Coimbra University Hospital, Coimbra, Portugal
| | - Margarida Gonçalo
- Department of Dermatology, Coimbra University Hospital, Coimbra, Portugal.,Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| |
Collapse
|
8
|
Saff RR. Skin testing as a biomarker in drug allergy. Ann Allergy Asthma Immunol 2023; 130:161-168. [PMID: 36243283 DOI: 10.1016/j.anai.2022.10.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Revised: 10/05/2022] [Accepted: 10/07/2022] [Indexed: 11/05/2022]
Abstract
Despite the significant negative impact drug allergies can have on patient care, the diagnosis is largely based on clinical history, and there are limited diagnostic tests that can be done at the time of a reaction. Biomarkers are needed to improve the diagnosis and the identification of the culprit medication. Skin testing is the most useful biomarker for immediate- and delayed-type reactions available, but it is limited by its low sensitivity. To improve its accuracy and reproducibility, a standardized procedure must be used. For immediate-type reactions, penicillin skin testing is the most widely studied, and it can be used in patients with history of anaphylaxis or recent immunoglobulin E-mediated reaction or for whom there is a significant risk if a reaction were to occur, such as pregnancy. Skin testing is also important in allergy to platinum agents allowing for continued first-line therapy. For delayed-type reactions, patch testing and delayed intradermal testing, used in conjunction with clinical history, can help to improve identification of the culprit medication depending on the type of reaction. Other biomarkers including in vitro testing for specific immunoglobulin E, basophil activation test, lymphocyte transformation test, ELISpot, and genetic factors that increase the likelihood of reaction are under investigation, and they may be most helpful when used in combination with the clinical history and skin testing results.
Collapse
Affiliation(s)
- Rebecca R Saff
- Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
| |
Collapse
|
9
|
Tsang DA, Lim SYD, Justin WSB, Hui LLY. Generalized Bullous Fixed Drug Eruption to Iodinated Contrast Media in Skin of Color. Am J Med 2022; 135:1326-1329. [PMID: 35901912 DOI: 10.1016/j.amjmed.2022.07.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 07/08/2022] [Accepted: 07/10/2022] [Indexed: 11/26/2022]
Affiliation(s)
- Denise Ann Tsang
- Department of Dermatology, Singapore General Hospital, Singapore.
| | | | | | - Laura Li Yao Hui
- Department of Dermatology, Singapore General Hospital, Singapore
| |
Collapse
|
10
|
Otsuka H, Fukumoto T, Oka M, Nishigori C. Case report: Severe non-pigmenting fixed drug eruption showing general symptoms caused by chondroitin sulfate sodium. Front Med (Lausanne) 2022; 9:1041492. [DOI: 10.3389/fmed.2022.1041492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2022] [Accepted: 10/04/2022] [Indexed: 11/13/2022] Open
Abstract
Non-pigmenting fixed drug eruption (NPFDE) is a subtype of fixed drug eruption (FDE) in which repeated eruptions occur at the same site. Clinically, NPFDE disappears without pigmentation changes; however, it sometimes causes fever or arthralgia. Its histopathological characteristics reportedly include infiltrations of CD8-positive T cells with a paucity of melanocytes as compared to FDE. We present the first case of severe NPFDE exhibiting general symptoms caused by chondroitin sulfate sodium. The patient was a 44-year-old man. Intravenous injection of chondroitin sulfate sodium caused erythema in the affected area. A histopathological examination of the biopsy tissue revealed infiltration of CD3-positive lymphocytes (both CD4-positive and CD8-positive lymphocytes) into the epidermis, minimal liquefaction degeneration in the basal layer of the epidermis, and few dermal melanophages, which may be responsible for non-pigmentation.
Collapse
|
11
|
Thaiwat S, Rojanapanthu P. Cutaneous adverse drug eruption: the role of drug patch testing. Int J Dermatol 2022; 62:108-114. [DOI: 10.1111/ijd.16398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 07/09/2022] [Accepted: 07/28/2022] [Indexed: 01/19/2023]
Affiliation(s)
- Supitchaya Thaiwat
- Division of Dermatology Department of Internal Medicine Phramongkutkloa Hospital Bangkok Thailand
| | - Pattareewan Rojanapanthu
- Division of Dermatology Department of Internal Medicine Phramongkutkloa Hospital Bangkok Thailand
| |
Collapse
|
12
|
McClatchy J, Yap T, Nirenberg A, Scardamaglia L. Fixed drug eruptions – the common and novel culprits since 2000. J Dtsch Dermatol Ges 2022; 20:1289-1302. [DOI: 10.1111/ddg.14870] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Accepted: 07/13/2022] [Indexed: 01/18/2023]
Affiliation(s)
- Jessica McClatchy
- Dermatology Department The Royal Melbourne Hospital Melbourne Australia
- Faculty of Medicine Dentistry and Health Sciences The University of Melbourne Melbourne Australia
| | - Tami Yap
- Dermatology Department The Royal Melbourne Hospital Melbourne Australia
- Faculty of Medicine Dentistry and Health Sciences The University of Melbourne Melbourne Australia
- Melbourne Dental School The University of Melbourne Melbourne Australia
| | - Alexander Nirenberg
- Dorevitch Pathology Melbourne Australia
- Australasian College of Cutaneous Oncology Melbourne Australia
| | - Laura Scardamaglia
- Dermatology Department The Royal Melbourne Hospital Melbourne Australia
- Faculty of Medicine Dentistry and Health Sciences The University of Melbourne Melbourne Australia
| |
Collapse
|
13
|
McClatchy J, Yap T, Nirenberg A, Scardamaglia L. Fixes Arzneimittelexanthem – häufige und neue Auslöser seit dem Jahr 2000. J Dtsch Dermatol Ges 2022; 20:1289-1303. [DOI: 10.1111/ddg.14870_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Accepted: 07/13/2022] [Indexed: 11/07/2022]
Affiliation(s)
- Jessica McClatchy
- Dermatology Department The Royal Melbourne Hospital Melbourne Australien
- Faculty of Medicine Dentistry and Health Sciences The University of Melbourne Melbourne Australien
| | - Tami Yap
- Dermatology Department The Royal Melbourne Hospital Melbourne Australien
- Faculty of Medicine Dentistry and Health Sciences The University of Melbourne Melbourne Australien
- Melbourne Dental School The University of Melbourne Melbourne Australien
| | - Alexander Nirenberg
- Dorevitch Pathology Melbourne Australien
- Australasian College of Cutaneous Oncology Melbourne Australien
| | - Laura Scardamaglia
- Dermatology Department The Royal Melbourne Hospital Melbourne Australien
- Faculty of Medicine Dentistry and Health Sciences The University of Melbourne Melbourne Australien
| |
Collapse
|
14
|
Calvão J, Figueiredo C, Gonçalo M. Patch testing in fixed drug eruptions: a 12-year retrospective study. J Eur Acad Dermatol Venereol 2022; 36:e770-e772. [PMID: 35656639 DOI: 10.1111/jdv.18290] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Accepted: 05/18/2022] [Indexed: 11/29/2022]
Affiliation(s)
- J Calvão
- Dermatovenereology Department of Coimbra University Hospital, Coimbra, Portugal
| | - C Figueiredo
- Dermatovenereology Department of Coimbra University Hospital, Coimbra, Portugal
| | - M Gonçalo
- Dermatovenereology Department of Coimbra University Hospital, Coimbra, Portugal.,Faculty of Medicine of Coimbra University Hospital
| |
Collapse
|
15
|
Barbaud A, Romano A. Skin Testing Approaches for Immediate and Delayed Hypersensitivity Reactions. Immunol Allergy Clin North Am 2022; 42:307-322. [DOI: 10.1016/j.iac.2022.01.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
16
|
Barbaud A, Castagna J, Soria A. Skin Tests in The Work-Up of Cutaneous Adverse Drug Reactions: A Review and Update. Contact Dermatitis 2022; 86:344-356. [PMID: 35122269 DOI: 10.1111/cod.14063] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 01/26/2022] [Accepted: 01/28/2022] [Indexed: 11/28/2022]
Affiliation(s)
- Annick Barbaud
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Sorbonne Université, Hôpital Tenon, Département de dermatologie et allergologie, Paris, France
| | - Julie Castagna
- AP-HP, Sorbonne Université, Hôpital Tenon, Département de dermatologie et allergologie, Paris, France
| | - Angèle Soria
- Sorbonne Université, INSERM 1135 Cimi-Paris, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Département de dermatologie et d'allergologie, 4 rue de la Chine, Paris
| |
Collapse
|
17
|
Woodruff CM, Botto N. The Role of Patch Testing in Evaluating Delayed Hypersensitivity Reactions to Medications. Clin Rev Allergy Immunol 2022; 62:548-561. [PMID: 35113364 PMCID: PMC9156465 DOI: 10.1007/s12016-022-08924-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/06/2022] [Indexed: 12/19/2022]
Abstract
Confirming drug imputability is an important step in the management of cutaneous adverse drug reactions (CADR). Re-challenge is inconvenient and in many cases life threatening. We review the literature on ideal patch testing technique for specific CADRs. Testing should be performed approximately 3 months after the resolution of the eruption using standard patch testing techniques. Commercially available patch test preparations are available for a minority of drugs, so in most cases, testing should be performed with the drug at various recommended concentrations and in different vehicles. Testing to all known excipients, such as dyes, vehicles and preservatives is also important. Immunosuppressive medications should be discontinued or down titrated to the lowest tolerable dose to decrease the risk of false negative reactions. We provide an overview of expert recommendations and extant evidence on the utility of patch testing for identifying the culprit drug in common CADRs and for specific drug or drug classes. Overall, there appears to be significant variability in the patch test positivity of different drugs, which is likely the result of factors intrinsic to the drug such as dermal absorption (as a function of lipophilicity and molecular size) and whether the drug itself or a downstream metabolite is implicated in the immune reaction. Drugs with high patch test positivity rates include beta-lactam antibiotics, aromatic anticonvulsants, phenytoin, and corticosteroids, among others. Patch testing positivity varies both as a function of the drug and type of CADR. The sum of the evidence suggests that patch testing in the setting of morbilliform eruptions, fixed drug eruption, acute generalized exanthematous pustulosis, and possibly also drug-induced hypersensitivity syndrome, photoallergic and eczematous reactions may be worthwhile, although utility of testing may vary on the specific drug in question for the eruption. It appears to be of limited utility and is not recommended in the setting of other complex CADR, such as SJS/TEN and leukocytoclastic vasculitis.
Collapse
Affiliation(s)
| | - Nina Botto
- University of California San Francisco, San Francisco, CA, USA
| |
Collapse
|
18
|
Ercan N. Mucosal fixed drug eruption to levetiracetam with early positive patch test on non-lesional skin. Pediatr Allergy Immunol 2022; 33:e13723. [PMID: 35212050 DOI: 10.1111/pai.13723] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2021] [Revised: 12/09/2021] [Accepted: 12/17/2021] [Indexed: 11/28/2022]
Affiliation(s)
- Nazli Ercan
- Division of Pediatric Allergy and Immunology, Department of Pediatrics, Gulhane Research and Training Hospital, University of Health Sciences Turkey, Ankara, Turkey
| |
Collapse
|
19
|
de-Andrés-Del-Rosario A, Marrero-Alemán G, Ramírez-Conchas JM, Pestana-Eliche M, Goday-Buján JJ, Sánchez-Machín I, Pérez-Robayna N. Fixed food eruption caused by soy lecithin in a child. Contact Dermatitis 2022; 86:429-431. [PMID: 35023195 DOI: 10.1111/cod.14047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2021] [Revised: 01/01/2022] [Accepted: 01/03/2022] [Indexed: 11/29/2022]
Affiliation(s)
| | - Gabriel Marrero-Alemán
- Department of Dermatology, Nuestra Señora de Candelaria University Hospital. S/C de Tenerife., Spain
| | | | - María Pestana-Eliche
- Department of Dermatology, Canarias University Hospital. La Laguna. Tenerife., Spain
| | | | | | - Nuria Pérez-Robayna
- Department of Dermatology, Canarias University Hospital. La Laguna. Tenerife., Spain
| |
Collapse
|
20
|
A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption. MEDICINA (KAUNAS, LITHUANIA) 2021; 57:medicina57090925. [PMID: 34577848 PMCID: PMC8468217 DOI: 10.3390/medicina57090925] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Revised: 08/28/2021] [Accepted: 08/29/2021] [Indexed: 11/24/2022]
Abstract
Fixed drug eruption (FDE) is a cutaneous adverse drug reaction characterized by the onset of rash at a fixed location on the body each time a specific medication is ingested. With each recurrence, the eruption can involve additional sites. Lesions can have overlying vesicles and/or bullae, and when they cover a significant percentage of body surface area, the eruption is referred to as generalized bullous fixed drug eruption (GBFDE). Due to the widespread skin denudation that can be seen in this condition, GBFDE may be confused clinically with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). While treatments described for GBFDE include supportive care, topical and/or systemic steroids, and, recently, cyclosporine, the mainstay of management involves identifying and discontinuing the causative drug. This review article will provide an overview of FDE with an emphasis on its generalized bullous variant.
Collapse
|
21
|
Bohne AS, Dietrich C, Morrison K, Schwarz T, Wehkamp U, Kaeding M. Two cases of quinine-induced fixed 'drug' eruption induced by long drinks. J Eur Acad Dermatol Venereol 2021; 35:e774-e776. [PMID: 34138490 DOI: 10.1111/jdv.17453] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- A S Bohne
- Department of Dermatology and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - C Dietrich
- Department of Dermatology and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - K Morrison
- Department of Dermatology and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - T Schwarz
- Department of Dermatology and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - U Wehkamp
- Department of Dermatology and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - M Kaeding
- Department of Dermatology and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| |
Collapse
|
22
|
Büyük Yaytokgil Ş, Güvenir H, Külhaş Celík İ, Yilmaz Topal Ö, Karaatmaca B, Civelek E, Toyran M, Dibek Misirlioğlu E. Evaluation of drug patch tests in children. Allergy Asthma Proc 2021; 42:167-174. [PMID: 33685563 DOI: 10.2500/aap.2021.42.200110] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Background: Patch tests are used to diagnose nonimmediate T-cell-mediated drug hypersensitivity reactions. The aim of this study was to evaluate the results of patch tests performed with suspect drugs in children. Methods: Patients < 18 years of age who had a drug patch test at the pediatric allergy outpatient clinic of our hospital between January 2014 and January 2020 were included in the study. Age, sex, culprit drug(s), reaction characteristics, and patch test results were recorded from the patients' files. Results: A total of 105 drug patch tests were performed on 71 patients during the study period. The patients' median age was 7 years (interquartile range, 4-11 years), and 57.7% (n = 41) were boys. Twenty-three patients (32.3%) had severe cutaneous adverse reaction (Stevens-Johnson syndrome in 11, drug reaction with eosinophilia and systemic symptoms in 9, and acute generalized exanthematous pustulosis in 3 patients), 45 (63.3%) had maculopapular rashes, and 3 (4.2%) had fixed drug eruption. A total of 20 patch test results (28%) were positive: 18 of 44 patch tests (40.9%) with antiepileptic drugs and 2 of 48 patch tests (4.1%) with antibiotics. Positive results were obtained in 23% of the patch tests (6/26) in 20 patients with severe cutaneous adverse reactions and in 17.7% of the patch tests (14/79) in 51 patients with mild cutaneous reactions. No adverse reactions occurred during or after the patch tests. Conclusion: In our study, patch test positivity was more common with antiepileptic drugs and in patients with severe cutaneous drug reaction.
Collapse
Affiliation(s)
- Şule Büyük Yaytokgil
- From the Division of Pediatric Allergy and Immunology, Ankara City Hospital, Ankara, Turkey
| | - Hakan Güvenir
- Division of Pediatric Allergy and Immunology, Malatya Education and Training Hospital, Malatya, Turkey; and
| | - İlknur Külhaş Celík
- From the Division of Pediatric Allergy and Immunology, Ankara City Hospital, Ankara, Turkey
| | - Özge Yilmaz Topal
- From the Division of Pediatric Allergy and Immunology, Ankara City Hospital, Ankara, Turkey
| | - Betül Karaatmaca
- From the Division of Pediatric Allergy and Immunology, Ankara City Hospital, Ankara, Turkey
| | - Ersoy Civelek
- Division of Pediatric Allergy and Immunology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
| | - Müge Toyran
- Division of Pediatric Allergy and Immunology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
| | - Emine Dibek Misirlioğlu
- Division of Pediatric Allergy and Immunology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
| |
Collapse
|
23
|
Kumagai J, Nakamura A, Ogawa S, Washio K. Intravaginal metronidazole ovule-related allergic contact dermatitis. Contact Dermatitis 2021; 85:85-86. [PMID: 33423284 DOI: 10.1111/cod.13782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Accepted: 01/06/2021] [Indexed: 12/01/2022]
Affiliation(s)
- Jun Kumagai
- Department of Dermatology, Kobe City Nishi-Kobe Medical Center, Kobe, Japan
| | - Ayaka Nakamura
- Department of Dermatology, Kobe City Nishi-Kobe Medical Center, Kobe, Japan
| | - Satoshi Ogawa
- Department of Dermatology, Kobe City Nishi-Kobe Medical Center, Kobe, Japan
| | - Ken Washio
- Department of Dermatology, Kobe City Nishi-Kobe Medical Center, Kobe, Japan
| |
Collapse
|
24
|
Patch Testing in Adverse Drug Reactions. Contact Dermatitis 2021. [DOI: 10.1007/978-3-030-36335-2_26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
25
|
Perks A, Bates TJ, Velangi S, Brown RM, Poveda-Gallego A. Probable etoricoxib-induced fixed drug eruption involving the oral mucosa: A case report. Oral Surg Oral Med Oral Pathol Oral Radiol 2020; 131:e100-e107. [PMID: 33468439 DOI: 10.1016/j.oooo.2020.12.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Revised: 12/18/2020] [Accepted: 12/18/2020] [Indexed: 11/15/2022]
Abstract
Fixed drug eruption (FDE) is a cutaneous adverse drug reaction characterized by recurrence of lesions at the same sites each time a specific drug is taken. Oral mucosal involvement is rare. Nonsteroidal anti-inflammatory drugs are one of the most common offending drug groups in FDE; however, selective cyclooxygenase-2 inhibitors, such as etoricoxib, are rarely implicated. We present a case of oral mucosal and cutaneous FDE induced by etoricoxib that, to the best of our knowledge, is the first reported case of this nature. We describe the diagnostic challenges and review the pertinent literature. The value of drug provocation testing and patch testing in FDE is also discussed.
Collapse
Affiliation(s)
- Alexandra Perks
- Oral Medicine, Birmingham Dental Hospital and School of Dentistry, Birmingham, UK.
| | - Timothy John Bates
- Oral Pathology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Birmingham, UK
| | - Shireen Velangi
- Dermatology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Birmingham, UK
| | - Rachel M Brown
- Oral Pathology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Birmingham, UK
| | - Ana Poveda-Gallego
- Oral Medicine, Birmingham Dental Hospital and School of Dentistry, Birmingham, UK
| |
Collapse
|
26
|
Jamiolkowski D, Steveling‐Klein E, Scherer Hofmeier K, Hartmann K. Multilocular bullous fixed drug eruption elicited by paracetamol and migraine attacks, but not by paracetamol alone. Contact Dermatitis 2020; 83:233-234. [DOI: 10.1111/cod.13567] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 04/16/2020] [Accepted: 04/17/2020] [Indexed: 11/28/2022]
Affiliation(s)
- Dagmar Jamiolkowski
- Division of Allergy, Department of DermatologyUniversity Hospital Basel Basel Switzerland
- Department of BiomedicineUniversity of Basel Basel Switzerland
| | - Esther Steveling‐Klein
- Division of Allergy, Department of DermatologyUniversity Hospital Basel Basel Switzerland
- Department of BiomedicineUniversity of Basel Basel Switzerland
| | - Kathrin Scherer Hofmeier
- Division of Allergy, Department of DermatologyUniversity Hospital Basel Basel Switzerland
- Department of BiomedicineUniversity of Basel Basel Switzerland
| | - Karin Hartmann
- Division of Allergy, Department of DermatologyUniversity Hospital Basel Basel Switzerland
- Department of BiomedicineUniversity of Basel Basel Switzerland
| |
Collapse
|
27
|
Calvão J, Cardoso JC, Gonçalo M. Fixed drug eruption to rupatadine with positive patch tests on non‐lesional skin. Contact Dermatitis 2020; 83:239-241. [DOI: 10.1111/cod.13576] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2020] [Accepted: 04/24/2020] [Indexed: 12/01/2022]
Affiliation(s)
- Joana Calvão
- Department of DermatologyCoimbra University Hospital Coimbra Portugal
| | - José C. Cardoso
- Department of DermatologyCoimbra University Hospital Coimbra Portugal
| | - Margarida Gonçalo
- Department of DermatologyCoimbra University Hospital Coimbra Portugal
- Faculty of MedicineUniversity of Coimbra Coimbra Portugal
| |
Collapse
|
28
|
Kutlu Ö, Demirbaş A, Elmas ÖF, Güvenç U, Metin A. Fixed drug eruption: A new side effect of bromelain. Contact Dermatitis 2020; 84:51-52. [PMID: 32648609 DOI: 10.1111/cod.13658] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Accepted: 07/08/2020] [Indexed: 11/29/2022]
Affiliation(s)
- Ömer Kutlu
- Department of Dermatology and Venereology, Uşak University, School of Medicine, Uşak, Turkey
| | - Abdullah Demirbaş
- Deparment of Dermatology and Venereology, Konya Numune Hospital, Konya, Turkey
| | - Ömer F Elmas
- Deparment of Dermatology and Venereology, Kırşehir Ahi Ervan University, School of Medicine, Kırşehir, Turkey
| | - Ulaş Güvenç
- Deparment of Dermatology and Venereology, Mersin Tarsus Medicalpark Hospital, Mersin, Turkey
| | - Ahmet Metin
- Department of Dermatology and Venereology, Uşak University, School of Medicine, Uşak, Turkey
| |
Collapse
|
29
|
Abstract
Drug eruptions in children are common but in general less studied than their adult counterparts. Aside from having significant impact on the child's health and quality of life, these reactions can limit what medications the patient can receive in the future. Familiarity with pediatric drug eruptions is important for accurate diagnosis and to prevent future recurrence or ineffective therapy. Our current understanding of how drug reactions differ mechanistically between children and adults is poor. There are multiple factors that could be contributing to the differing incidence, presentation, and treatment modalities offered to pediatric versus adult patients. For many of these cutaneous drug reactions, the treatment regime is not standardized, being based primarily on case reports. Although not comprehensive, this review highlights common pediatric drug eruption patterns and discuss diagnostic mimickers. Five cutaneous adverse drug reactions in the pediatric population are presented: morbilliform (exanthematous) eruptions, urticarial eruptions, serum sickness-like reactions, fixed drug eruptions, and DRESS syndrome. Clinical features, diagnostic workup, and management are discussed with an emphasis on the pediatric population.
Collapse
Affiliation(s)
- EmilyD Nguyen
- Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA; Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, USA
| | - Colleen K Gabel
- Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA; University of Massachusetts Medical School, Worcester, Massachusetts, USA
| | - JiaDe Yu
- Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
| |
Collapse
|
30
|
Patel S, John AM, Handler MZ, Schwartz RA. Fixed Drug Eruptions: An Update, Emphasizing the Potentially Lethal Generalized Bullous Fixed Drug Eruption. Am J Clin Dermatol 2020; 21:393-399. [PMID: 32002848 DOI: 10.1007/s40257-020-00505-3] [Citation(s) in RCA: 49] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
A fixed drug eruption (FDE) is a relatively common reaction associated with more than 100 medications. It is defined as a same-site recurrence with exposure to a particular medication. The primary approach and treatment for all types of FDEs are to identify and remove the causative agent, often accomplished by a thorough history of medication and other chemical exposures, and possibly prior episodes. The most common category of FDE, localized FDE, whether bullous or non-bullous, is self-limited. Although one can confirm the causative agent using oral challenge testing, it is not recommended due to the risk of severe exacerbation or possible generalization; patch testing is now preferred. Bullous FDE may resemble erythema multiforme. Treatment of localized FDE includes medication removal, patient counseling, and symptomatic relief. Failure to remove the causative agent in localized FDE can lead to recurrence, which is associated with increased inflammation, hyperpigmentation, and risk of a potentially lethal generalized bullous FDE (GBFDE), which may resemble Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Distinguishing GBFDE from SJS and TEN is salient and will be stressed: GBFDE has more rapid onset in 1-24 h rather than in weeks, less or no mucosal involvement, less or no systemic involvement, and a tendency for a more favorable prognosis; however, recent experience suggests it may be just as life-threatening. This review will provide a comprehensive update and approach to diagnosis and management.
Collapse
Affiliation(s)
- Shreya Patel
- Dermatology, Rutgers New Jersey Medical School, 185 South Orange Avenue, Medical Science Building H-576, Newark, NJ, 07103-2757, USA
| | - Ann M John
- Dermatology, Robert Wood Johnson University Hospital, One World's Fair Drive, Suite 2400, Somerset, NJ, 08873, USA
| | - Marc Zachary Handler
- Dermatology, Rutgers New Jersey Medical School, 185 South Orange Avenue, Medical Science Building H-576, Newark, NJ, 07103-2757, USA
| | - Robert A Schwartz
- Dermatology, Rutgers New Jersey Medical School, 185 South Orange Avenue, Medical Science Building H-576, Newark, NJ, 07103-2757, USA.
| |
Collapse
|
31
|
Affiliation(s)
- Mitsuhito Ota
- Department of Dermatology, Chitose City Hospital, Chitose, Japan
| |
Collapse
|
32
|
|
33
|
Gleeson P, Tanaka TI, Alawi F, Alhendi F, Fadugba O. Fixed Drug Eruption of the Tongue Due to Trimethoprim-Sulfamethoxazole. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE 2019; 8:328-329.e1. [PMID: 31519543 DOI: 10.1016/j.jaip.2019.08.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Revised: 08/09/2019] [Accepted: 08/13/2019] [Indexed: 11/27/2022]
Affiliation(s)
- Patrick Gleeson
- Section of Allergy and Immunology, Division of Pulmonary, Allergy, and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa.
| | - Takako I Tanaka
- Department of Oral Medicine, University of Pennsylvania School of Dental Medicine, Philadelphia, Pa
| | - Faizan Alawi
- Section of Oral Pathology, Division of Dermatopathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa
| | - Fatmah Alhendi
- Department of Oral Medicine, University of Pennsylvania School of Dental Medicine, Philadelphia, Pa
| | - Olajumoke Fadugba
- Section of Allergy and Immunology, Division of Pulmonary, Allergy, and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa
| |
Collapse
|
34
|
Sai Pawan AR, Swamy VHT, Mothi SN, Yashaswini Y. Ibuprofen‐induced intra‐oral fixed drug eruption. JOURNAL OF PHARMACY PRACTICE AND RESEARCH 2019. [DOI: 10.1002/jppr.1530] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. R. Sai Pawan
- Department of Pharmacy Practice Vikas College of Pharmaceutical Sciences Rayangudem India
| | | | - S. N. Mothi
- Asha Kirana Hospital and HIV Care Clinic Mysuru India
| | - Y. Yashaswini
- Department of Pharmacy Practice Vikas College of Pharmaceutical Sciences Rayangudem India
| |
Collapse
|
35
|
Ben Fadhel N, Chaabane A, Ammar H, Ben Romdhane H, Soua Y, Chadli Z, Zili J, Boughattas NA, Ben Fredj N, Aouam K. Clinical features, culprit drugs, and allergology workup in 41 cases of fixed drug eruption. Contact Dermatitis 2019; 81:336-340. [DOI: 10.1111/cod.13351] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2019] [Revised: 07/04/2019] [Accepted: 07/09/2019] [Indexed: 11/29/2022]
Affiliation(s)
- Najah Ben Fadhel
- University Hospital of Fattouma Bourguiba of Monastir, Department of PharmacologyUniversity of Monastir Monastir Tunisia
| | - Amel Chaabane
- University Hospital of Fattouma Bourguiba of Monastir, Department of PharmacologyUniversity of Monastir Monastir Tunisia
| | - Helmi Ammar
- University Hospital of Fattouma Bourguiba of Monastir, Department of PharmacologyUniversity of Monastir Monastir Tunisia
| | - Haifa Ben Romdhane
- University Hospital of Fattouma Bourguiba of Monastir, Department of PharmacologyUniversity of Monastir Monastir Tunisia
| | - Yosra Soua
- University Hospital of Fattouma Bourguiba of Monastir, Department of DermatologyUniversity of Monastir Monastir Tunisia
| | - Zohra Chadli
- University Hospital of Fattouma Bourguiba of Monastir, Department of PharmacologyUniversity of Monastir Monastir Tunisia
| | - Jameleddine Zili
- University Hospital of Fattouma Bourguiba of Monastir, Department of DermatologyUniversity of Monastir Monastir Tunisia
| | - Naceur A. Boughattas
- University Hospital of Fattouma Bourguiba of Monastir, Department of PharmacologyUniversity of Monastir Monastir Tunisia
| | - Nadia Ben Fredj
- University Hospital of Fattouma Bourguiba of Monastir, Department of PharmacologyUniversity of Monastir Monastir Tunisia
| | - Karim Aouam
- University Hospital of Fattouma Bourguiba of Monastir, Department of PharmacologyUniversity of Monastir Monastir Tunisia
| |
Collapse
|
36
|
Yung CC, Watts TJ, Haque R. Successful desensitization to metronidazole in a patient with generalized fixed drug eruption. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE 2019; 8:769-771.e1. [PMID: 31369825 DOI: 10.1016/j.jaip.2019.07.020] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 06/10/2019] [Accepted: 07/16/2019] [Indexed: 10/26/2022]
Affiliation(s)
- Ching Ching Yung
- Department of Adult Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
| | - Timothy J Watts
- Department of Adult Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
| | - Rubaiyat Haque
- Department of Adult Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
| |
Collapse
|
37
|
Miroux‐Catarino A, Silva L, Amaro C, Ferreira ML, Viana I. Bullous fixed drug eruption induced by etoricoxib, confirmed by patch testing, with tolerance to celecoxib. Contact Dermatitis 2019; 81:388-389. [DOI: 10.1111/cod.13339] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2019] [Accepted: 06/17/2019] [Indexed: 11/29/2022]
Affiliation(s)
| | - Leandro Silva
- Dermatology Department, Hospital Egas MonizCentro Hospitalar de Lisboa Ocidental Lisbon Portugal
| | - Cristina Amaro
- Dermatology Department, Hospital Egas MonizCentro Hospitalar de Lisboa Ocidental Lisbon Portugal
| | - Maria L. Ferreira
- Dermatology Department, Hospital Egas MonizCentro Hospitalar de Lisboa Ocidental Lisbon Portugal
| | - Isabel Viana
- Dermatology Department, Hospital Egas MonizCentro Hospitalar de Lisboa Ocidental Lisbon Portugal
| |
Collapse
|
38
|
Carneiro-Leão L, Rodrigues Cernadas J. Bullous Fixed Drug Eruption Caused by Etoricoxib Confirmed by Patch Testing. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE 2019; 7:1629-1630. [DOI: 10.1016/j.jaip.2019.01.032] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Accepted: 01/16/2019] [Indexed: 10/27/2022]
|
39
|
Kalogirou EM, Tosios KI. Fixed drug eruption on the tongue associated with piroxicam: report of two cases and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 2019; 127:393-398. [DOI: 10.1016/j.oooo.2019.01.073] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2018] [Revised: 01/14/2019] [Accepted: 01/18/2019] [Indexed: 11/27/2022]
|
40
|
Stingeni L, Bianchi L, Hansel K, Corazza M, Gallo R, Guarneri F, Patruno C, Rigano L, Romita P, Pigatto PD, Calzavara-Pinton P. Italian Guidelines in Patch Testing - adapted from the European Society of Contact Dermatitis (ESCD). GIORN ITAL DERMAT V 2019; 154:227-253. [DOI: 10.23736/s0392-0488.19.06301-6] [Citation(s) in RCA: 72] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
41
|
Ben Romdhane H, Ammar H, Ben Fadhel N, Chadli Z, Ben Fredj N, Boughattas NA, Chaabane A, Aouam K. Piroxicam‐induced fixed drug eruption: Cross‐reactivity with meloxicam. Contact Dermatitis 2019; 81:24-26. [DOI: 10.1111/cod.13225] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Revised: 01/15/2019] [Accepted: 01/16/2019] [Indexed: 10/27/2022]
Affiliation(s)
- Haifa Ben Romdhane
- Faculty of Medicine, Department of Pharmacology, EPS Fattouma Bourguiba University of Monastir Monastir Tunisia
| | - Helmi Ammar
- Faculty of Medicine, Department of Pharmacology, EPS Fattouma Bourguiba University of Monastir Monastir Tunisia
| | - Najeh Ben Fadhel
- Faculty of Medicine, Department of Pharmacology, EPS Fattouma Bourguiba University of Monastir Monastir Tunisia
| | - Zohra Chadli
- Faculty of Medicine, Department of Pharmacology, EPS Fattouma Bourguiba University of Monastir Monastir Tunisia
| | - Nadia Ben Fredj
- Faculty of Medicine, Department of Pharmacology, EPS Fattouma Bourguiba University of Monastir Monastir Tunisia
| | - Naceur A. Boughattas
- Faculty of Medicine, Department of Pharmacology, EPS Fattouma Bourguiba University of Monastir Monastir Tunisia
| | - Amel Chaabane
- Faculty of Medicine, Department of Pharmacology, EPS Fattouma Bourguiba University of Monastir Monastir Tunisia
| | - Karim Aouam
- Faculty of Medicine, Department of Pharmacology, EPS Fattouma Bourguiba University of Monastir Monastir Tunisia
| |
Collapse
|
42
|
Usefulness of Cutaneous Provocation Tests to Study Drugs Responsible for Cutaneous Adverse Drug Reactions. CURRENT TREATMENT OPTIONS IN ALLERGY 2019. [DOI: 10.1007/s40521-019-0198-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
43
|
Broche C, Pralong P, Gil H, Yahiaoui N, Mousseau M, Chatain C, Jacquier JP, Charles J, Leccia MT. Fixed drug eruption caused by fulvestrant confirmed by skin tests: First case. Contact Dermatitis 2018; 80:184-186. [PMID: 30461027 DOI: 10.1111/cod.13161] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2018] [Revised: 10/12/2018] [Accepted: 10/14/2018] [Indexed: 11/27/2022]
Affiliation(s)
- Clémentine Broche
- Dermatology, Allergology and Photobiology Department, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
| | - Pauline Pralong
- Dermatology, Allergology and Photobiology Department, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
| | - Hugo Gil
- Anatomopathology Department, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
| | - Nassima Yahiaoui
- Regional Pharmacovigilance, Addictovigilance Department, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
| | - Mireille Mousseau
- Oncology Department, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
| | - Catharina Chatain
- Dermatology, Allergology and Photobiology Department, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
| | - Jean-Pierre Jacquier
- Dermatology, Allergology and Photobiology Department, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
| | - Julie Charles
- Dermatology, Allergology and Photobiology Department, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
| | - Marie-Thérèse Leccia
- Dermatology, Allergology and Photobiology Department, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
| |
Collapse
|
44
|
Pipet A, Rochefort-Morel C, Drouet M, Nicolie B, Bernier C, Hoarau C, Marty C, Magnan A. Comments on Ben Mansour et al: Additional cases of multifocal fixed drug eruption to ceftazidime. Pediatr Allergy Immunol 2018. [PMID: 29537668 DOI: 10.1111/pai.12886] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- A Pipet
- Plate-Forme Transversale d'Allergologie, Centre Hospitalo-Universitaire de Nantes, Nantes, France
| | - C Rochefort-Morel
- Allergologie, Centre Hospitalo-Universitaire de Rennes, Rennes, France
| | - M Drouet
- Département d'Allergologie, Centre Hospitalo-Universitaire d'Angers, Angers, France
| | - B Nicolie
- Département d'Allergologie, Centre Hospitalo-Universitaire d'Angers, Angers, France
| | - C Bernier
- Plate-Forme Transversale d'Allergologie, Centre Hospitalo-Universitaire de Nantes, Nantes, France
| | - C Hoarau
- Allergologie, Centre Hospitalo-Universitaire de Tours, Tours, France
| | - C Marty
- Pneumologie et Allergologie, Centre Hospitalier de Saint Nazaire, Saint Nazaire, France
| | - A Magnan
- Plate-Forme Transversale d'Allergologie, Centre Hospitalo-Universitaire de Nantes, Nantes, France
| |
Collapse
|
45
|
Marques LP, Villarinho ALCF, Melo MDGM, Torre MGS. Fixed drug eruption to nimesulide: an exuberant presentation confirmed by patch testing. An Bras Dermatol 2018; 93:470-472. [PMID: 29924254 PMCID: PMC6001078 DOI: 10.1590/abd1806-4841.20187338] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2017] [Accepted: 11/26/2017] [Indexed: 11/22/2022] Open
Affiliation(s)
| | - Ana Luiza Castro Fernandes Villarinho
- Occupational Dermatology Department, Occupational Health Studies
and Human Ecology Center, Escola Nacional de Saúde Pública Sergio
Arouca, Fundação Oswaldo Cruz (Cesteh-Ensp- Fiocruz), Rio de Janeiro
(RJ), Brazil
| | - Maria das Graças Mota Melo
- Occupational Dermatology Department, Occupational Health Studies
and Human Ecology Center, Escola Nacional de Saúde Pública Sergio
Arouca, Fundação Oswaldo Cruz (Cesteh-Ensp- Fiocruz), Rio de Janeiro
(RJ), Brazil
| | | |
Collapse
|
46
|
Gabrielli S, Langlois A, Ben-Shoshan M. Prevalence of Hypersensitivity Reactions in Children Associated with Acetaminophen: A Systematic Review and Meta-Analysis. Int Arch Allergy Immunol 2018; 176:106-114. [DOI: 10.1159/000487556] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Accepted: 01/24/2018] [Indexed: 11/19/2022] Open
|
47
|
Barbaud A. Investigations allergologiques dans les érythèmes pigmentés fixes. Méthode recommandée par le groupe FISARD de la SFD. Ann Dermatol Venereol 2018; 145:210-213. [DOI: 10.1016/j.annder.2018.01.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Accepted: 01/04/2018] [Indexed: 12/01/2022]
|
48
|
Kulhas Celik İ, Buyuktiryaki B, Misirlioglu ED, Hasbek E, Kocabas CN. Fixed Drug Eruption Related to Cefixime in an Adolescent Case. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE 2018; 6:1742-1743. [PMID: 29339130 DOI: 10.1016/j.jaip.2017.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Revised: 11/30/2017] [Accepted: 12/11/2017] [Indexed: 10/18/2022]
Affiliation(s)
- İlknur Kulhas Celik
- Division of Pediatric Allergy and Immunology, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - Betul Buyuktiryaki
- Division of Pediatric Allergy and Immunology, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - Emine Dibek Misirlioglu
- Division of Pediatric Allergy and Immunology, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - Ezgi Hasbek
- Department of Pediatrics, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - Can Naci Kocabas
- Division of Pediatric Allergy and Immunology, Mugla Sitki Kocman University School of Medicine, Mugla, Turkey.
| |
Collapse
|
49
|
Jun E, Kim SC, Lee CM, Oh J, Lee S, Shim IK. Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft. Sci Rep 2017; 7:12381. [PMID: 28959053 PMCID: PMC5620083 DOI: 10.1038/s41598-017-12670-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2017] [Accepted: 09/18/2017] [Indexed: 01/07/2023] Open
Abstract
Pancreatic cancer has a high rate of local recurrence and poor prognosis even with adjuvant chemotherapy after curative resection. The aim of this study was to investigate if local drug delivery combined with low dose systemic chemotherapy can increase the therapeutic effect of chemotherapy while reducing systemic toxicities. Poly-L-lactic acid-based 5-FU releasing patch was fabricated by electrospinning, and its tumour killing effects were first confirmed in vitro. The 5-FU patch directly adhered to the tumour in subcutaneous and orthotopic murine models, and induced a significant decrease in tumour size. Systemic gemcitabine treatment group, 5-FU drug releasing patch group, and systemic gemcitabine plus 5-FU patch group were compared by tumour size measurement, non-invasive bio-imaging, and histology in subcutaneous models. Combination of local drug patch and systemic chemotherapy led to increased tumour suppression effects that lasted longer, as well as increased survival rate. Histology revealed higher degree of apoptosis in the combined group. Systemic toxicity was recovered within 7 days after the treatment in all mice. Conclusively, local drug delivery using biocompatible polymer patch significantly inhibited tumour growth, and combination with systemic chemotherapy was more effective than single systemic chemotherapy.
Collapse
Affiliation(s)
- Eunsung Jun
- Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine & Asan Medical Center, 388-1 Pungnap-2 Dong, Songpa-gu, Seoul, South Korea.,Department of Biomedical Sciences, University of Ulsan College of Medicine, 388-1 Pungnap-2 Dong, Songpa-gu, Seoul, South Korea
| | - Song Cheol Kim
- Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine & Asan Medical Center, 388-1 Pungnap-2 Dong, Songpa-gu, Seoul, South Korea.
| | - Chan Mi Lee
- Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine & Asan Medical Center, 388-1 Pungnap-2 Dong, Songpa-gu, Seoul, South Korea
| | - Juyun Oh
- Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine & Asan Medical Center, 388-1 Pungnap-2 Dong, Songpa-gu, Seoul, South Korea
| | - Song Lee
- Asan Institute for Life Science, University of Ulsan College of Medicine and Asan Medical Center, 388-1 Pungnap-2 Dong, Songpa-gu, Seoul, South Korea
| | - In Kyong Shim
- Asan Institute for Life Science, University of Ulsan College of Medicine and Asan Medical Center, 388-1 Pungnap-2 Dong, Songpa-gu, Seoul, South Korea
| |
Collapse
|
50
|
Romano A, Valluzzi RL, Caruso C, Maggioletti M, Gaeta F. Non-immediate Cutaneous Reactions to Beta-Lactams: Approach to Diagnosis. Curr Allergy Asthma Rep 2017; 17:23. [PMID: 28382604 DOI: 10.1007/s11882-017-0691-4] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Non-immediate cutaneous reactions (i.e., occurring at least 1 h after the initial drug administration), particularly maculopapular exanthemas and urticarial eruptions, are common during beta-lactam treatments. A T cell-mediated pathogenic mechanism has been demonstrated in some cutaneous reactions, such as maculopapular exanthema, fixed drug eruption, acute generalized exanthematous pustulosis, and drug-induced hypersensitivity syndrome. In the diagnostic work-up, patch testing is useful, together with delayed-reading intradermal testing. Patch tests are a simple and safe diagnostic tool, which in the case of severe reactions should be used as the first line of investigation. However, patch tests are less sensitive than intradermal tests, which are preferable in subjects with mild reactions. Lymphocyte transformation or activation tests and enzyme-linked immunosorbent spot assays can be used as complementary tests. In selected cases of mild or moderate reactions, displaying negative results in the aforesaid allergy tests, a graded challenge with the implicated beta-lactam can be performed.
Collapse
Affiliation(s)
- Antonino Romano
- Allergy Unit, Presidio Columbus, Via G. Moscati, 31, 00168, Rome, Italy. .,IRCCS Oasi Maria S.S, Troina, Italy.
| | - Rocco Luigi Valluzzi
- Allergy Unit, Presidio Columbus, Via G. Moscati, 31, 00168, Rome, Italy.,Department of Pediatrics, Division of Allergy, Pediatric Hospital Bambino Gesù, Rome, Vatican City, Italy
| | - Cristiano Caruso
- Allergy Unit, Presidio Columbus, Via G. Moscati, 31, 00168, Rome, Italy
| | | | - Francesco Gaeta
- Allergy Unit, Presidio Columbus, Via G. Moscati, 31, 00168, Rome, Italy
| |
Collapse
|